Menu
Back to Archived Journals » Core Evidence » Volume 1-Issues 1 & 2
Core Evidence ceased publishing in March 2023. All articles that have been published in Core Evidence will continue to be available on the Dove Press site, and will be securely archived with CLOCKSS.
Core Evidence
ISSN: 1555-175X
- View all (143)
- Volume 15, 2020 (4)
- Volume 14, 2019 (6)
- Volume 13, 2018 (3)
- Volume 12, 2017 (2)
- Volume 11, 2016 (5)
- Volume 10, 2015 (9)
- Volume 9, 2014 (13)
- Volume 8, 2013 (7)
- Volume 7, 2012 (12)
- Volume 6, 2011 (7)
- Volume 5, 2010 (9)
- Volume 4, 2009 (20)
- Volume 3, 2008 (5)
- Volume 2, 2007 (22)
- Volume 1-Issues 3 & 4, 2006 (8)
- Volume 1-Issues 1 & 2, 2005 (11)
Archive: Volume 1-Issues 1 & 2, 2005
Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia
Sonya Haslam
Core Evidence 2005, 1-Issues 1 & 2:0-0
Published Date: 31 March 2005
Aliskiren in hypertension: evidence for its potential therapeutic value
Doris Peter
Core Evidence 2005, 1-Issues 1 & 2:0-0
Published Date: 31 March 2005
Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease
Linda Timm Wagner, Charlotte A. Kenreigh
Core Evidence 2005, 1-Issues 1 & 2:0-0
Published Date: 31 March 2005
Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes
William Winlow
Core Evidence 2005, 1-Issues 1 & 2:0-0
Published Date: 31 March 2005
Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value
Carole Nadin
Core Evidence 2005, 1-Issues 1 & 2:0-0
Published Date: 31 March 2005
Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes
Andrew Thomson
Core Evidence 2005, 1-Issues 1 & 2:0-0
Published Date: 31 March 2005